
https://www.science.org/content/blog-post/all-bets-are-now-officially
# All Bets Are Now Officially Off (January 2004)

## 1. SUMMARY

The article discusses the genomics gold rush of the late 1990s and early 2000s, where investors poured money into gene sequencing companies believing that knowing gene sequences would directly reveal useful drug targets. The author describes various complications that made this approach more difficult than initially hoped—from RNA splicing to the inability to predict protein structures from sequence alone. 

The central development discussed is a January 2004 Nature paper by J.C. Yang's lab at the National Cancer Institute reporting the first observation of protein splicing in mammalian cells. This phenomenon, where protein fragments are spliced back together in new combinations after being chopped from larger precursors, was previously known only in single-celled organisms and plants. The article notes that this discovery further complicated the assumption that genomic sequences directly predict all functional proteins, since such spliced proteins would be literally invisible to pure genomic analysis.

## 2. HISTORY

Protein splicing research did indeed advance significantly after 2004, but in measured ways:

**Scientific Developments:**
- Protein splicing (intein-mediated) became recognized as an important but relatively rare mechanism in eukaryotes
- Research expanded into understanding the biochemical mechanisms and biological functions
- The phenomenon did not fundamentally undermine genomics, but rather became part of the broader understanding that genotype-to-phenotype mapping is more complex than linear sequence→protein relationships

**Impact on Biotechnology/Pharmaceutical Industry:**
- Genomics companies continued operating, though the "gold rush" enthusiasm moderated. Many shifted toward more comprehensive approaches integrating multiple data types
- The biotech sector by the mid-2000s had already moved beyond the pure "sequence everything" phase toward more sophisticated target validation approaches
- No major pharmaceutical companies were derailed by this discovery; instead, it was absorbed as one of many complexities in drug development

**Drug Development:**
- I am not confident about specific drugs that resulted directly from protein splicing research
- The overall genomics approach adapted rather than collapsed, with sequencing remaining central to drug discovery but with greater appreciation for proteomics, structural biology, and systems biology

**Business Impact:**
- Companies specializing in proteomics and protein analysis continued developing alongside genomics firms
- The article's suggestion that this might be "Nobel material" proved overstated in terms of immediate industry disruption

## 3. PREDICTIONS

• **"This paper... has already set off a flurry of research"** – *TRUE*. Research on protein splicing expanded after 2004, though I cannot provide specific citations or quantify the scale.

• **"Perhaps there are some unexplained proteomic problems out there which this will turn out to answer"** – *PARTIALLY TRUE*. Protein splicing did help explain certain biochemical phenomena, but it did not revolutionize proteomics at the scale initially imagined.

• **"If this turns out to be physiologically important, it's Nobel material for sure"** – *FALSE/EXAGGERATED*. While scientifically significant, protein splicing did not receive Nobel recognition and did not fundamentally undermine the genomics paradigm in the dramatic way the article suggested.

• **The broader concern about genomics investment being "another hit"** – *PARTIALLY TRUE, OVERSOLD*. The genomics sector did see consolidation and re-evaluation in the mid-2000s, but this was due to broader factors (commercial challenges, regulatory hurdles, scientific complexity) rather than primarily protein splicing. Genomics remained central to biotechnology.

• **"Any bets are now officially off"** (implied prediction that genomics approach would be invalidated) – *FALSE*. Genomics continued as a productive approach, supplemented by proteomics, structural biology, and systems approaches rather than replaced by them.

## 4. INTEREST

Rating: **4/10**

This article captures an interesting moment in biotechnology thinking—the transition from genomics hype to more nuanced understanding—but overestimates the revolutionary impact of protein splicing on the field. While scientifically accurate in describing the discovery, it presents the finding with more dramatic implications than ultimately materialized.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20040118-all-bets-are-now-officially.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_